Accessibility Menu
GlucoTrack logo

GlucoTrack(NASDAQ) GCTK

Current Price$0.32
Market Cap$2.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-100%
5 Year-100%
1 Year-96%
1 Month-16%
GlucoTrack last closing stock price
MetricPriceDate
Last closeUSD 0.312026-07-22
GlucoTrack stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-42.17%USD 0.532026-07-15
1 month-15.94%USD 0.362026-06-22
3 month-58.06%USD 0.732026-04-23
Year to date-92.1%USD 3.872025-12-31
1 year-95.75%USD 7.202025-07-22
3 year-99.99%USD 2,160.002023-07-21
5 year-100%USD 46,800.002021-07-23
Since inception-100%USD 487,500.492013-04-25

GlucoTrack Financials at a Glance

Market Cap

$2.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$16.89M

EPS (TTM)

-$20.88

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

0.75 (Low)

Price

$0.32

Volume

345,189

Open

$0.31

Previous Close

$0.31

Daily Range

$0.30 - $0.32

52-Week Range

$0.29 - $14.14

Estimated Earnings Date

Mar 30, 2026

GCTK News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GlucoTrack

GlucoTrack develops implantable devices to help people with diabetes monitor blood sugar painlessly. Its main product gives real-time glucose readings without finger pricks. This technology aims to make daily diabetes management easier and less intrusive.

Gadgets for Glucose: What GlucoTrack Sells

  • Implantable Glucose Monitor: A device placed under the skin to track blood sugar continuously for people with diabetes. (0% of revenue; pre-commercial)
  • Research Initiatives: Studies on glucose sensing for patients considering spinal cord stimulation therapy. (0% of revenue)
  • Intellectual Property: Patents for sensor longevity and low-power implantable devices. (No direct revenue contribution)

Plot Twists: Growth and Expansion Moves

  • Shifted focus in 2023 from earlobe sensor to implantable monitor.
  • Completed first human study of implantable device in 2025.
  • Preparing for U.S. clinical trials, with regulatory engagement ongoing since the second quarter of 2025.
  • Developed early reimbursement strategies and began exploring cardiovascular device models in 2025.
  • Expanded patent portfolio with three new U.S. patents in 2025.

What Makes GlucoTrack Stand Out (Besides the Name)

GlucoTrack’s implantable sensor aims for longer use and real-time accuracy, unlike many current monitors. The company holds patents for sensor durability and minimal calibration needs. Its technology targets comfort and convenience for people managing diabetes daily.

Five Things You Need to Know

  • Revenue was $0 in QQ3 2025, unchanged from QQ3 2024 and QQ3 2023.
  • Net loss was $-4 million in QQ3 2025, up 32.5% from QQ3 2024.
  • Cash and cash equivalents were $7.4 million as of December 31, 2025.
  • Operating expenses were $-4 million in QQ3 2025, down 18% from QQ3 2024.
  • Company has not yet commercialized any products and faces ongoing funding needs.

Bottom Line

GlucoTrack has shifted from non-invasive to implantable glucose monitoring, focusing on innovation and clinical validation. The company remains pre-revenue and relies on new funding to continue development.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

15

CEO

Paul V. Goode, PhD

Website

www.glucotrack.com

Headquarters

Rutherford, NJ 7760049, US

GCTK Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-581.98%

Return on Capital

-562.39%

Return on Assets

-387.72%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.72M

Volume

345.19K

Avg. Volume

6.67M

Financials (TTM)

Gross Profit

-$22.00K

Operating Income

-$8.18M

EBITDA

-$16.97M

Operating Cash Flow

-$16.35M

Capital Expenditure

-$87.00K

Free Cash Flow

-$16.44M

Cash & ST Invst.

$3.93M

Total Debt

$26.00K

GlucoTrack Performance Analysis

GlucoTrack annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
GlucoTrack sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
GlucoTrack annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,719.608.9%
20232023-12-31USD -2,298.2433.6%
20242024-12-31USD -4,106.4178.7%
20252025-12-31USD -31.22-99.2%
GlucoTrack sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3076.1%
Q32025-09-30148.2%
Q42025-12-31-185.8%
Q12026-03-31166.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$22.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$157.42K

N/A

Employees

15

N/A

Net Income

-$4.33M

+36.6%

EBITDA

-$4.31M

+36.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.93M

-56.8%

Total Debt

$26.00K

-90.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$26.00K

-25.7%

Return on Assets

-3.88%

N/A

Return on Invested Capital

13.21%

N/A

Free Cash Flow

-$4.05M

-37.3%

Operating Cash Flow

-$4.05M

-37.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RDHLRedHill Biopharma Ltd.
$0.67-2.47%
BBLGBone Biologics Corporation
$1.08-1.82%
BGMSBio Green Med Solution, Inc.
$0.88-2.23%
NAOVNanoVibronix, Inc.
$1.90+1.06%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
NOKNokia
$9.73-0.05%
AALAmerican Airlines Group
$13.56-0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$66.30-0.06%

Questions About GCTK

What is the current price of GlucoTrack?

GlucoTrack is trading at $0.31 per share.

What is the 52-week range for GlucoTrack?

Over the past 52 weeks, GlucoTrack has traded between $0.29 and $14.14.

How much debt does GlucoTrack have?

As of the most recent reporting period, GlucoTrack reported total debt of $3.59M.

How much cash does GlucoTrack have on hand?

GlucoTrack reported $3.93M in cash and cash equivalents in its most recent financial results.

What is GlucoTrack’s dividend yield?

GlucoTrack does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services